Mateusz Antoszewski

Mateusz Antoszewski

Auto-generated profile, based on publicly available information

Mateusz Antoszewski

Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Nature Immunology
Verified
Journal Article
Open access
PDF file
RVRichard A. Voit
Richard A. Voit
LTLiming Tao
Liming Tao
FYFulong Yu
Fulong Yu
LCLiam D. Cato
Liam D. Cato
BCBlake Cohen
Blake Cohen
VSVijay G. Sankaran
Vijay G. Sankaran
The molecular regulation of human hematopoietic stem cell (HSC) maintenance is therapeutically important, but limitations in experimental systems and interspecies variation have constrained our knowledge of this process. Here, we have studied a rare genetic disorder due to MECOM haploinsufficiency, characterized by an early-onset absence of HSCs in vivo. By generating a faithful model of this disorder in primary human HSCs and coupling functional studies with integrative single-cell genomic analyses, we uncover a key transcriptional network involving hundreds of genes that is required for HSC maintenance. Through our analyses, we nominate cooperating transcriptional regulators and identify how MECOM prevents the CTCF-dependent genome reorganization that occurs as HSCs differentiate. We show that this transcriptional network is co-opted in high-risk leukemias, thereby enabling these cancers to acquire stem cell properties. Collectively, we illuminate a regulatory network necessary for HSC self-renewal through the study of a rare experiment of nature.

3 June 2021 in Blood
Verified
Journal Article
Closed access
PDF file
DTDelphine Tardivon
Delphine Tardivon
MAMateusz Antoszewski
Mateusz Antoszewski
NZNadine Zangger
Nadine Zangger
MNMarianne Nkosi
Marianne Nkosi
JSJessica Sordet-Dessimoz
Jessica Sordet-Dessimoz
FRFreddy Radtke
Freddy Radtke
NOTCH1 gain-of-function mutations are recurrent in B cell chronic lymphocytic leukemia (B-CLL), where they are associated with accelerated disease progression and refractoriness to chemotherapy. The specific role of NOTCH1 in the development and progression of this malignancy is unclear. Herein we assess the impact of loss of Notch signaling and pathway hyperactivation in an in vivo mouse model of CLL (IgH.TEm) that faithfully recapitulates many features of the human pathology. Ablation of canonical Notch signaling using conditional gene inactivation of RBP-J in immature hematopoietic or B cell progenitors delayed CLL induction and reduced incidence of mice developing disease. In contrast, forced expression of a dominant active form of Notch resulted in more animals developing CLL with early disease onset. Comparative analysis of gene expression and epigenetic features of Notch gain-of-function and control CLL cells revealed direct and indirect regulation of cell cycle-associated genes, which led to increased proliferation of Notch gain-of-function CLL cells in vivo. These results demonstrate that Notch signaling facilitates disease initiation and promotes CLL cell proliferation and disease progression.

7 March 2025 in Nature Aging
Verified
Journal Article
Open access
PDF file
LJLorna Jayne
Lorna Jayne
ALAurora Lavin-Peter
Aurora Lavin-Peter
JRJulian Roessler
Julian Roessler
ATAlexander Tyshkovskiy
Alexander Tyshkovskiy
MAMateusz Antoszewski
Mateusz Antoszewski
SHSinisa Hrvatin
Sinisa Hrvatin
Torpor and hibernation are extreme physiological adaptations of homeotherms associated with pro-longevity effects. Yet the underlying mechanisms of how torpor affects aging, and whether hypothermic and hypometabolic states can be induced to slow aging and increase healthspan, remain unknown. Here we demonstrate that the activity of a spatially defined neuronal population in the preoptic area, which has previously been identified as a torpor-regulating brain region, is sufficient to induce a torpor-like state (TLS) in mice. Prolonged induction of TLS slows epigenetic aging across multiple tissues and improves healthspan. We isolate the effects of decreased metabolic rate, long-term caloric restriction, and decreased core body temperature (Tb) on blood epigenetic aging and find that the decelerating effect of TLSs on aging is mediated by decreased Tb. Taken together, our findings provide novel mechanistic insight into the decelerating effects of torpor and hibernation on aging and support the growing body of evidence that Tb is an important mediator of the aging processes.

18 November 2025 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
LVLucrezia della Volpe
Lucrezia della Volpe
ALAndrew J. Lee
Andrew J. Lee
MAMateusz Antoszewski
Mateusz Antoszewski
ADAmy Deik
Amy Deik
KSKsenia R. Safina
Ksenia R. Safina
VSVijay G. Sankaran
Vijay G. Sankaran
Improved ex vivo expansion of human haematopoietic stem cells (HSCs) would considerably advance transplantation and genome-engineered therapies, yet existing culture methods still allow substantial HSC loss. Here we show that this attrition is driven largely by ferroptosis, a metabolically regulated, iron-dependent cell-death pathway, and that it can be blocked to augment HSC expansion. Inhibiting ferroptosis with liproxstatin-1 or ferrostatin-1 markedly increases the expansion of cord blood and adult HSCs consistently across donors in both widely used serum-free cultures and recently reported chemically defined conditions. The expanded cells retain phenotypic and molecular stem cell identity and mediate improved durable, multilineage engraftment in xenotransplanted mice without genotoxicity or aberrant haematopoiesis. Mechanistically, ferroptosis blockade is accompanied by upregulated ribosome biogenesis and cholesterol synthesis, increasing levels of 7-dehydrocholesterol—a potent endogenous ferroptosis inhibitor that itself promotes HSC expansion. Crucially, this approach enhances yields of therapeutically genome-modified HSCs, paving a path for clinical applications.

1 January 2026 in Science
Verified
Journal Article
Closed access
GAGaurav Agarwal
Gaurav Agarwal
MAMateusz Antoszewski
Mateusz Antoszewski
XXXueqin Xie
Xueqin Xie
YPYash Pershad
Yash Pershad
UAUma P. Arora
Uma P. Arora
VSVijay G. Sankaran
Vijay G. Sankaran
Somatic mutations that increase the fitness of hematopoietic stem cells (HSCs) drive their expansion in clonal hematopoiesis (CH) and predispose individuals to blood cancers. Population variation in the growth rate and potential of mutant clones suggests that genetic factors may confer resilience against CH. Here, we identified a noncoding regulatory variant, rs17834140-T, that protects against CH and myeloid malignancies by selectively down-regulating the RNA-binding protein MSI2 in HSCs. By modeling variant effects and mapping MSI2 binding targets, we uncovered an RNA network that maintains human HSCs and influences CH risk. Variant rs17834140-T was associated with slower CH expansion, and stem cell MSI2 levels modified ASXL1 -mutant HSC clonal dominance. These findings leverage natural resilience to illuminate posttranscriptional regulation in human HSCs, suggesting that inhibition of MSI2 or its targets could be rational strategies for blood cancer prevention.

21 April 2022 in Blood
Verified
Journal Article
Open access
PDF file
MAMateusz Antoszewski
Mateusz Antoszewski
NFNadine Fournier
Nadine Fournier
GBGustavo A. Ruiz Buendía
Gustavo A. Ruiz Buendía
JLJoao Lourenco
Joao Lourenco
YLYuanlong Liu
Yuanlong Liu
FRFreddy Radtke
Freddy Radtke
NOTCH1 is a well-established lineage specifier for T cells and among the most frequently mutated genes throughout all subclasses of T cell acute lymphoblastic leukemia (T-ALL). How oncogenic NOTCH1 signaling launches a leukemia-prone chromatin landscape during T-ALL initiation is unknown. Here we demonstrate an essential role for the high-mobility-group transcription factor Tcf1 in orchestrating chromatin accessibility and topology, allowing aberrant Notch1 signaling to convey its oncogenic function. Although essential, Tcf1 is not sufficient to initiate leukemia. The formation of a leukemia-prone epigenetic landscape at the distal Notch1-regulated Myc enhancer, which is fundamental to this disease, is Tcf1-dependent and occurs within the earliest progenitor stage even before cells adopt a T lymphocyte or leukemic fate. Moreover, we discovered a unique evolutionarily conserved Tcf1-regulated enhancer element in the distal Myc-enhancer, which is important for the transition of preleukemic cells to full-blown disease.